The August 2024 reporting season has reached its halfway point, and thus far market earnings growth expectations have shifted slightly lower, with roughly twice as many consensus downgrades than upgrades (from the companies that have reported already).
The ASX 300 is now expected to deliver EPS growth of ~4.5% over the next twelve months, with the lacklustre outlook for resources earnings offset by strong growth expectations for the IT (+30%), Healthcare (+24%), and Consumer Discretionary (+10%) sectors.
More downgrades than upgrades
The market has reacted rationally to results so far this reporting season. Companies with FY24 earnings beats and FY25 guidance upgrades have outperformed this month-to-date on average, while companies that have missed consensus expectations have been punished by investors.
Based on our analysis of major results so far, companies with earnings 'beats' have outperformed the ASX 300 by an average of ~6% this month to date, while ‘misses’ have underperformed the market by ~7%, and companies with ‘in line’ results and guidance have generally market-performed. See figure 2.
In this report, we detail noteworthy results and changes that have been made to the Focus Portfolio, including:
- Netwealth (NWL) has been removed from the portfolio (-3%).
- James Hardie (JHX) has been added to the portfolio ahead of US interest rate cuts and an expected improvement in the US housing market (+3%).
- CSL FY24 result – no changes to our position with our investment thesis still intact.
- Commonwealth Bank (CBA) FY24 result – no changes to our underweight stance.
Netwealth – Taking Profits
Netwealth (NWL) has been removed from the Focus Portfolio (-3%)
In FY24, NWL posted strong EPS growth of +24%, although this was slightly below consensus expectations of +28%. The update has driven minor consensus downgrades to EPS growth forecasts for FY25, primarily due to an increased rate of reinvestment by the business.
While NWL remains a high-quality business with a strong medium-term earnings growth outlook supported by market share gains from incumbent legacy platform providers, after modest downgrades the company’s valuation has become increasingly demanding at a forward PE of ~52x.
Therefore, with limited valuation upside at current levels, we are taking profits from NWL by removing it from the Focus Portfolio.
Adding James Hardie – Positioning for US Rate Cuts
James Hardie (JHX) has been added to the Focus Portfolio at a 3% weight
JHX was removed from the portfolio in January 2024 (at a share price of ~$57), primarily on valuation grounds and due to near-term consensus earnings risks heading into its 3Q24 result.
Since then, however, the macro outlook has changed dramatically, with US interest rate cuts now highly likely to commence when the Fed meets next month.
Over the last month, we have flagged that we have been actively looking for opportunities to increase our exposure to high-quality global cyclicals to position the portfolio ahead of US interest rate cuts. JHX is one of the companies that we noted was on our ‘watch list’ of potential buying opportunities.
As a building materials manufacturer with significant end-market exposure to US housing (representing ~84% of FY25e group EBIT), JHX will be an early beneficiary of the Fed’s policy easing cycle.
1Q25 update drives modest analyst downgrades
In Q1, JHX posted NPAT growth of +2%, which was 6% ahead of consensus expectations.
JHX also reaffirmed its North American volume guidance of “+/- low single digit %” growth in FY25, although management flagged ongoing US housing market softness, which has resulted in minor consensus downgrades to FY25 consensus forecasts.
Looking through the immediate headwinds, now is an opportune time to invest in JHX to position the portfolio in advance of US interest rate cuts.
Our investment thesis for JHX is based on two key points:
1. Interest rate cuts will support a recovery in US housing construction activity
US housing market activity has fallen significantly since 2022, following successive interest rate hikes and amidst affordability challenges that have weighed on housing construction volumes.
Builder sentiment is weak and new housing starts are currently depressed at four-year lows, which has driven significant downgrades to JHX's consensus North American fibre volumes over FY25-26.
However, with Fed rate cuts likely in September, we expect US housing market sentiment and construction activity to recover, which presents upside risks to JHX’s North American earnings over the medium-term (particularly considering the conservative posture of consensus estimates following downgrades).
An improved macro outlook should also allow JHX’s valuation multiple to re-rate higher, noting the company trades at a meaningful discount to where it traded during the last Fed easing cycle.
In any case, JHX offers attractive value at its current forward PE of 20x considering a consensus EPS CAGR of ~20% between FY26-27 (with risks skewed to the upside).
2. Structural growth tailwinds
Leaving aside the more supportive macro outlook, JHX is also exposed to significant structural tailwinds that have underpinned its two decade-long run of above-system growth, which we expect to continue over the medium and long-term, driven by:
- Fibre cement share gains –
JHX is the global leader in fibre cement (with ~90% US category share), which is used on the external walls of homes and building facades. Over the last two decades, fibre cement has grown in popularity in the US due to its superior aesthetics and durability, and its lower lifetime cost compared to alternatives like vinyl and timber. Given fibre cement is currently used in 22% of new US housing construction, there is still a long runway for growth over the long-term. - US housing shortage -
Since the GFC, the US housing market has been chronically underbuilt, with household formations significantly outpacing new home completions. A significant ‘catch-up’ of new construction activity is needed, which would drive increased demand for building materials, including fibre cement. - Ageing US housing stock -
The median US single family home is the oldest it has ever been, at > 40 years old. This is likely to drive growth in repair & remodelling demand (JHX’s focus), as old and deteriorating structures will need to be renovated.
CSL – Thesis Intact with Margin Recovery on Track
CSL is held in the Focus Portfolio at an 8% weight
CSL reported NPATA growth of +15% (constant currency) in FY24, which was at the top end of its guidance. FY25 guidance for NPATA growth of 10-13% (constant currency) was slightly below consensus expectations, resulting in minor (low single-digit) downgrades to consensus forecasts.
Notwithstanding downgrades to Vifor, driven by the soft outlook for its iron franchise, our thesis for CSL remains intact – which is centered on the growth of its core Behring segment driven by its ongoing margin recovery.
Pleasingly, in FY24 Behring’s gross margins expanded by +120bps (constant currency), which will continue over the medium-term driven by the roll-out of the Rika donation system (driving a lower plasma costs per litre), along with further growth in volumes and subsequent operating leverage.
In summary, with Behring’s margin trajectory being the key to CSL’s earnings growth outlook, our favourable view towards CSL remains unchanged, despite weakness within its smaller segments. At a forward PE of ~30x, CSL continues to offer growth at a reasonable price given its three-year EPS CAGR of ~14%.
CBA – Still Unmoved
CBA is not held in the Focus Portfolio, making it the portfolio’s largest underweight exposure
CBA’s full-year result was broadly in line with consensus expectations, as its cash NPAT fell -2% in FY24.
There were no major surprises in the result, although the highlight was that NIMs stabilised in 2H24, while expected credit losses held up better than expected despite macro headwinds. Together, these factors underpinned minor consensus EPS upgrades.
With that being said, asset quality is deteriorating, with arrears and troublesome & impaired assets continuing to rise. This indicates that bad debts will increase further over the medium-term.
Everything considered, this was a sound, but largely in-line result from CBA, which has triggered only minor upgrades to consensus forecasts – and no changes to our cautious stance. At a forward PE of 24x, CBA’s valuation remains unattractive considering its (still) lacklustre earnings growth outlook over FY25-FY26.
| Company Name | Ticker | Period | Earnings Comment | 12 month forward EPS revisions |
|
last 30 days |
last 90 days |
||||
| Amcor | AMC | FY | In line. Key highlights included AMC's strong cost control (reflected in higher EBIT margins despite soft volumes) and the 5% sequential improvement in group volumes in Q4. In line with AMC’s guidance, we expect the normalisation of volume growth from an end to customer de-stocking to underpin a return to positive (mid to high single digit) EPS growth in FY25/26. | 2% | 2% |
| ANZ | ANZ | Q3 | In line. Limited detail provided, albeit a lower credit loss ratio and liquidity coverage ratio suggests its NIM has improved sequentially (in line with peers), which should drive minor (low single digit) EPS upgrades. | 1% | 1% |
| Arcadium Lithium | LTM | HY | Beat. Notwithstanding the challenging environment for lithium miners, this was a positive update with LTM tracking towards the higher end of its cost savings guidance range LTM also announced a pause in two expansion projects, reducing expected capex requirements by ~$500 million over the next 24 months. LTM's cost savings and prudent capital allocation leaves it well placed to weather lower lithium prices until they recover. | -14% | -15% |
| CAR Group | CAR | FY | In line. Recent portfolio addition. In FY24, CAR reported NPAT and proforma EBITDA growth of +24% and 17% respectively, broadly in line with consensus expectations. Pleasingly, management’s outlook pointed to robust trading conditions across key segments supporting ‘good’ group EBITDA growth in FY25. | -2% | -1% |
| Evolution Mining | EVN | FY | In line. This was a strong beat to consensus earnings in FY24, while production and capex guidance for FY25 was in line with consensus, which is a key positive for EVN after a period of successive guidance downgrades over the last 12 months. Our investment thesis remains intact, with EVN demonstrating significant improvements in operating cash flows which are set to continue in FY25. | -2% | -11% |
| Goodman Group | GMG | FY | Broadly in line. EPS growth of +14% in FY24 met consensus, while FY25 guidance for EPS growth of +9% (vs consensus of +12%) should be viewed as broadly in line with expectations given GMG's tendency to upgrade through the year. However, we are disappointed by the lack of visible benefits from GMG’s data centre pivot in its guidance (which suggests growth is decelerating). As such, we remain cautious and are comfortable retaining a neutral stance to GMG (after trimming our position in July) given its full valuation multiple. | 1% | 4% |
| HealthCo REIT | HCW | FY | In line. Overall, this was a positive update with 100% rent collections and 99% occupancy maintained. HCW reaffirmed the strength of its financial and legal position regarding the ongoing restructure of Healthscope, its largest tenant. Pleasingly, management is proactively addressing its ~30% NTA discount by extending its asset recycling program and through its ongoing $50m on-market buyback (14% complete). | -2% | -1% |
| NAB | NAB | Q3 | In line. Cash earnings benefitted from a stable NIM vs its 1H24 average (in line with peers). Lower bad debt charges leaves NAB on track to meet 2H24 consensus expectations. | 1% | 1% |
| Resmed | RMD | FY | Guidance Above Consensus. Strong result with +19.9% NPAT growth underpinned by 330bps of gross margin expansion (constant currency) driven by lower freight costs, easing COGS, and mix shift benefits associated with strong growth in higher margin mask and software sales. Pleasingly, FY25 gross margin guidance of 59-60% was well ahead of the consensus of 57.7%, which drove upgrades. | 3% | 2% |
| Westpac | WBC | Q3 | Modest beat. Overall, this was solid trading update, with modest upgrades expected for NIMs and bad and doubtful debts (in line with peers), based on its current run-rate relative to 2H24 consensus. |
2% | 2% |
Source: Refinitiv, Wilsons Advisory.
Written by
Greg Burke, Equity Strategist
Greg is an Equity Strategist in the Investment Strategy team at Wilsons Advisory. He is the lead portfolio manager of the Wilsons Advisory Australian Equity Focus Portfolio and is responsible for the ongoing management of the Global Equity Opportunities List.
About Wilsons Advisory: Wilsons Advisory is a financial advisory firm focused on delivering strategic and investment advice for people with ambition – whether they be a private investor, corporate, fund manager or global institution. Its client-first, whole of firm approach allows Wilsons Advisory to partner with clients for the long-term and provide the wide range of financial and advisory services they may require throughout their financial future. Wilsons Advisory is staff-owned and has offices across Australia.
Disclaimer: This communication has been prepared by Wilsons Advisory and Stockbroking Limited (ACN 010 529 665; AFSL 238375) and/or Wilsons Corporate Finance Limited (ACN 057 547 323; AFSL 238383) (collectively “Wilsons Advisory”). It is being supplied to you solely for your information and no action should be taken on the basis of or in reliance on this communication. To the extent that any information prepared by Wilsons Advisory contains a financial product advice, it is general advice only and has been prepared by Wilsons Advisory without reference to your objectives, financial situation or needs. You should consider the appropriateness of the advice in light of your own objectives, financial situation and needs before following or relying on the advice. You should also obtain a copy of, and consider, any relevant disclosure document before making any decision to acquire or dispose of a financial product. Wilsons Advisory's Financial Services Guide is available at wilsonsadvisory.com.au/disclosures.
All investments carry risk. Different investment strategies can carry different levels of risk, depending on the assets that make up that strategy. The value of investments and the level of returns will vary. Future returns may differ from past returns and past performance is not a reliable guide to future performance. On that basis, any advice should not be relied on to make any investment decisions without first consulting with your financial adviser. If you do not currently have an adviser, please contact us and we would be happy to connect you with a Wilsons Advisory representative.
To the extent that any specific documents or products are referred to, please also ensure that you obtain the relevant disclosure documents such as Product Disclosure Statement(s), Prospectus(es) and Investment Program(s) before considering any related investments.
Wilsons Advisory and their associates may have received and may continue to receive fees from any company or companies referred to in this communication (the “Companies”) in relation to corporate advisory, underwriting or other professional investment services. Please see relevant Wilsons Advisory disclosures at www.wilsonsadvisory.com.au/disclosures.